Boston Scientific Announces Global Restructuring, Q2 Results Beat Estimates
Boston Scientific disclosed a global restructuring program on July 21, 2026, aiming for cost efficiencies and growth, with $700-$800 million in costs and $500 million in annual pre-tax savings, including headcount reductions. The company reported Q2 2026 earnings of $0.86 per share on $5.44 billion revenue, beating expectations, but trimmed its full-year outlook due to competitive dynamics. Shares initially rose then fell over 5% after the restructuring news.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Boston Scientific beats Q2 expectations, raises full-year outlook
Boston Scientific reported second-quarter 2026 results that exceeded analyst expectations, with adjusted EPS of $0.86 versus $0.83 consensus and revenue of $5.442 billion versus $5.37 billion expected. Revenue grew 7.5% on a reported basis year-over-year. The company raised its full-year sales outlook. The Cardiovascular segment led growth with an 8.3% sales increase, while MedSurg grew 5.9%. Geographically, Latin America and Canada posted the strongest growth at 22.4%. Boston Scientific also completed a $2 billion accelerated share repurchase program, buying back approximately 40 million shares. CEO Mike Mahoney cited disciplined execution and confidence in long-term growth. Shares rose 1.3% in after-hours trading.
Boston Scientific beats Q2 expectations, raises full-year outlook
Boston Scientific reported second-quarter results that beat analyst expectations, with adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.442 billion versus $5.37 billion expected. Revenue grew 7.5% reported and 7.0% operationally year-over-year. GAAP net income rose to $907 million from $797 million a year earlier. The Cardiovascular segment led growth with sales up 8.3%, while MedSurg rose 5.9%. Geographically, Latin America and Canada posted the strongest growth at 22.4% reported, followed by Asia-Pacific at 11.2%. The company completed its $2 billion accelerated share repurchase program, buying back about 40 million shares. CEO Mike Mahoney cited disciplined execution and confidence in long-term growth. Shares rose 1.3% in after-hours trading.
Boston Scientific Reports Strong Q2 Results but Lowers 2026 Outlook Amid Restructuring
Boston Scientific reported Q2 2026 revenues of approximately $5.4 billion, a 7.5% year-over-year increase, driven by its cardiovascular segment (up 8.3% to $3.6 billion) and adoption of the FARAPULSE pulsed field ablation system. The medsurg business generated $1.8 billion. Despite the positive quarter, the company trimmed its full-year 2026 outlook, now expecting EPS between $3.28 and $3.32 (down from $3.34-$3.41) and sales growth of 5.5%-6.5% (down from 7%-8.5%). The revision is attributed to a global restructuring program announced in an SEC filing, aimed at achieving sustained cost efficiencies. The plan, expected to cost $700-$800 million and be completed by 2029, is projected to reduce annual pre-tax expenses by approximately $500 million. Following the announcement, Boston Scientific's share price fell over 5% to $42.67. CEO Mike Mahoney expressed confidence in long-term growth driven by innovation and category leadership.
Show 6 older updatesHide older updates
Boston Scientific Reports Positive Q2 Results but Trims 2026 Outlook
Boston Scientific reported Q2 2026 revenues of approximately $5.4 billion, a 7.5% year-over-year increase, driven by its cardiovascular segment (up 8.3% to $3.6 billion) and adoption of the FARAPULSE PFA system. Despite the positive results, the company trimmed its full-year 2026 earnings per share guidance to $3.28-$3.32 (from $3.34-$3.41) and lowered sales growth expectations to 5.5%-6.5% (from 7%-8.5%). The tempered outlook is partly attributed to a global restructuring program announced in an SEC filing, expected to cost $700-$800 million through 2029 but reduce annual pre-tax expenses by approximately $500 million. Following the announcement, Boston Scientific's share price fell over 5% to $42.67. CEO Mike Mahoney expressed confidence in long-term growth driven by innovation and category leadership.
Boston Scientific Q2 2026 Earnings: Profit Forecast Cut on Watchman Slowdown
Boston Scientific reported second-quarter 2026 net sales of $5.44 billion and adjusted earnings of $0.86 per share, beating its own guidance and analyst expectations. However, the company trimmed its full-year adjusted earnings per share forecast to $3.28-$3.32 from $3.34-$3.41, citing weaker-than-expected demand for its Watchman heart implant. The Watchman device, used to prevent strokes in atrial fibrillation patients, is seeing slower dedicated-case volumes as doctors increasingly combine the procedure with other heart surgeries. Boston Scientific also lowered its full-year organic sales growth outlook to 5%-6% from 6.5%-8%. The cardiovascular segment posted $3.62 billion in sales (up 8.3%), while MedSurg generated $1.82 billion (up 5.9%). The company's board approved a broad restructuring initiative on July 21, targeting completion by late 2029. Shares rose nearly 4% in premarket trading following the quarterly beat. CEO Mike Mahoney expressed confidence in long-term growth despite near-term headwinds.
Boston Scientific Beats Q2 Expectations on Broad Sales Growth, Shares Rise
Boston Scientific (NYSE: BSX) reported second-quarter earnings and revenue that exceeded Wall Street expectations, driving shares up over 3% in pre-market trading. The medical device manufacturer posted earnings per share of $0.86, beating the consensus estimate of $0.83, while revenue reached $5.44 billion, surpassing the expected $5.37 billion. Growth was broad-based across both core divisions: the MedSurg segment grew 5.9% and the Cardiovascular segment grew 8.3%. Internationally, Asia-Pacific led with 11.2% sales growth, while Latin America and Canada surged 22.4%. CEO Mike Mahoney highlighted disciplined execution and long-term category leadership strategy. However, the company's full-year EPS guidance of $3.28-$3.32 fell short of the $3.36 consensus, and Q3 guidance of $0.80-$0.82 also missed expectations of $0.84. The company maintained its organic sales growth forecast of 5-6% for the year.
Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares
Boston Scientific (NYSE:BSX) reported second-quarter earnings of $0.86 per share, beating the consensus estimate of $0.83, and revenue of $5.44 billion, surpassing expectations of $5.37 billion. Shares rose over 3% in pre-market trading. Growth was broad-based, with the MedSurg segment up 5.9% and Cardiovascular up 8.3%. International markets performed strongly, especially Asia-Pacific (11.2% growth) and Latin America/Canada (22.4% reported growth). CEO Mike Mahoney highlighted disciplined execution and long-term growth strategy. However, the company's full-year earnings guidance of $3.28-$3.32 per share fell below the consensus of $3.36, and Q3 guidance of $0.80-$0.82 also missed expectations of $0.84. The company maintained its organic sales growth forecast of 5-6% for the year.
Boston Scientific expects headcount reductions amid restructuring initiative
Boston Scientific announced a global restructuring program on July 21, 2026, aimed at driving sustained cost efficiencies and supporting growth. The plan, disclosed in an SEC filing on July 27, includes supply chain optimization, production line transfers, and functional transformation, expected to be largely completed by the end of 2029. The medtech giant estimates the restructuring will cost between $700 million and $800 million, with $600-700 million in future cash outlays, and is expected to reduce annual pre-tax expenses by approximately $500 million. While new jobs will be created, the company expects headcount reductions, with up to $300 million allocated for terminations. Boston Scientific's stock rose 2.85% to $45.51 on the NYSE following the announcement. The company is set to release its Q2 results on July 29, after trimming its full-year outlook by 2% at the top end due to competitive dynamics.
Boston Scientific expects headcount reductions amid restructuring initiative
Boston Scientific announced a global restructuring program on July 21, 2026, aimed at driving sustained cost efficiencies and supporting growth. The plan, disclosed in an SEC filing on July 27, includes supply chain optimization, production line transfers, and functional transformation, expected to be largely completed by end of 2029. The medtech giant estimates costs between $700 million and $800 million, with $600-$700 million in future cash outlays, and expects annual pre-tax expense reductions of approximately $500 million. While new jobs will be created, the company anticipates headcount reductions, with up to $300 million allocated for terminations. Boston Scientific's stock rose 2.85% to $45.51 on July 27. The company is set to release Q2 results on July 29, after trimming its full-year outlook by 2% due to competitive dynamics.